Navire Pharma
Navire Pharma is a biotechnology company focused on developing SHP2 inhibitors as targeted therapies for difficult-to-treat cancers. Their mission is to harness advances in understanding SHP2’s role in cancer signaling to create novel treatments, aiming to bring safe and effective therapies to market rapidly. They are a subsidiary of BridgeBio Pharma and collaborate with leading cancer research institutions.
Industries
Nr. of Employees
small (1-50)
Navire Pharma
Patents
Products
Clinical-stage SHP2 inhibitor candidate
A clinical-stage small-molecule SHP2 inhibitor being evaluated in Phase 1 studies for advanced solid tumors driven by MAPK pathway alterations (e.g., RAS and receptor tyrosine kinase mutations).
Clinical-stage SHP2 inhibitor candidate
A clinical-stage small-molecule SHP2 inhibitor being evaluated in Phase 1 studies for advanced solid tumors driven by MAPK pathway alterations (e.g., RAS and receptor tyrosine kinase mutations).
Services
Design and execution of in vitro and in vivo studies to evaluate candidate small molecules for anti-tumor activity and combination potential.
Execution of Phase 1 clinical studies to assess safety, tolerability and preliminary efficacy of a clinical-stage SHP2 inhibitor in patients with advanced solid tumors.
Establishing and managing licensing agreements and clinical collaborations to support development and commercialization across territories.
Design and execution of in vitro and in vivo studies to evaluate candidate small molecules for anti-tumor activity and combination potential.
Execution of Phase 1 clinical studies to assess safety, tolerability and preliminary efficacy of a clinical-stage SHP2 inhibitor in patients with advanced solid tumors.
Establishing and managing licensing agreements and clinical collaborations to support development and commercialization across territories.
Expertise Areas
- Targeted oncology drug discovery
- SHP2 pathway biology
- Preclinical pharmacology and translational research
- Early-phase clinical development (Phase 1)
Key Technologies
- Allosteric small-molecule inhibitors
- Molecular-glue design
- In vitro cell-based assays
- In vivo tumor xenograft models